Clinical Trials
UK To Give Faster Clinical Trial Nods Following Setbacks
The UK government intends to make clinical trials more accessible in order to re-establish the country's reputation as a favoured location for pioneering research.
In a new initiative to jump-start the country's faltering life sciences goals, the Medicines and Healthcare...
Clinical Trials
4-Year Study On Cystic Fibrosis Patients Shows Efficacy
The combination of modulator therapies tezacaftor (TEZ) and ivacaftor (IVA) for cystic fibrosis (CF) has shown long-term safety as well as clinical benefit in a trial that lasted four years.
Both the CF modulators were assessed across the age group...
Clinical Trials
$15m Mitochondrial Clinical Trial Headed by Australian University
Almost 50 children in Australia are born every year with a devastating mitochondrial disease that has an expected lifespan of just 5 years. In a first in Australia, the Medical Research Future Fund has gone on to announce $15...
Clinical Trials
Intracranial Pressure Reduced Through Injectable Peptide
It has come to light that patient with idiopathic intracranial hypertension- IIH can be treated with an injectable peptide used for type 2 diabetes. This has been found in a Phase II trial. As per the study’s latest findings,...
Clinical Trials
Greenphire Expands Agreement with Merck to Help Reduce Financial and Travel Barriers for Clinical Trial Participants Worldwide
Greenphire, the global leader in financial lifecycle management for clinical trials, today announced an expansion of its agreement with Merck, known as MSD outside the United States and Canada. This expanded agreement now includes the use of Greenphire's ClinCard...
Clinical Trials
Shuttle Pharmaceuticals Engages UI Pharmaceuticals for Formulation and Clinical Batch Manufacture of Ropidoxuridine for Brain Tumor Clinical Trial
Shuttle Pharmaceuticals Holdings, Inc., a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced it has signed an agreement with the University of Iowa (UI) Pharmaceuticals...
Clinical Trials
LEO Pharma and ICON Enter a Strategic Partnership to Propel Clinical Trial Execution Within Medical Dermatology
LEO Pharma, a global leader in medical dermatology, and ICON plc announced a strategic partnership that will enable LEO Pharma to scale clinical trial execution that is patient-centric and cost effective, and which will support the company’s overall ambition...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read